Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 4573 · Innovate to Save Lives Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

26 U.S.C. § 41 Credit for increasing research activities

+27 −2Shown
More for 26 U.S.C. § 41
Read § 41Only this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    Section 41(a) of the Internal Revenue Code of 1986 is amended by striking and at the end of paragraph (2), by striking the period at the end of paragraph (3) and inserting , and, and by adding at the end the following new paragraph:(4) in the case of a small business (as defined in subsection (b)(3)(D)(iii)), 10 percent of the qualified drug threat mitigation research expenses (as defined in subsection (i)) for the taxable year..

  2. Carried out:

    Section 41(a) of the Internal Revenue Code of 1986 is amended by striking and at the end of paragraph (2), by striking the period at the end of paragraph (3) and inserting , and, and by adding at the end the following new paragraph:(4) in the case of a small business (as defined in subsection (b)(3)(D)(iii)), 10 percent of the qualified drug threat mitigation research expenses (as defined in subsection (i)) for the taxable year..

  3. Carried out:

    Section 41(a) of the Internal Revenue Code of 1986 is amended by striking and at the end of paragraph (2), by striking the period at the end of paragraph (3) and inserting , and, and by adding at the end the following new paragraph:(4) in the case of a small business (as defined in subsection (b)(3)(D)(iii)), 10 percent of the qualified drug threat mitigation research expenses (as defined in subsection (i)) for the taxable year..

  4. Carried out:

    Section 41 of such Code is amended by adding at the end the following new subsection:(i) Qualified drug threat mitigation research expenses.— For purposes of this section— (1) Qualified drug threat mitigation research expenses.— The term “qualified drug threat mitigation research expenses” means the qualified research expenses which would be determined under …

§ 41(a)–(b)

Start of § 41 to (a)(1)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(1)(B)(B) (B)
the base amount,the base amount,
(a)(2)(2) (2)
20 percent of the basic research payments determined under subsection (e)(1)(A),[struck: and]20 percent of the basic research payments determined under subsection (e)(1)(A),
(a)(3)(3) (3)
20 percent of the amounts paid or incurred by the taxpayer in carrying on any trade or business of the taxpayer during the taxable year (including as contributions) to an energy research consortium for energy research[struck: .]20 percent of the amounts paid or incurred by the taxpayer in carrying on any trade or business of the taxpayer during the taxable year (including as contributions) to an energy research consortium for energy research[inserted: , and]
(a)(4)(4) [inserted: ]
[inserted: in the case of a small business (as defined in subsection (b)(3)(D)(iii)), 10 percent of the qualified drug threat mitigation research expenses (as defined in subsection (i)) for the taxable year.]
(b)(b) Qualified research expenses(b) Qualified research expenses
For purposes of this section—For purposes of this section—
(b)(1)(1) Qualified research expenses(1) Qualified research expenses
The term “qualified research expenses” means the sum of the following amounts which are paid or incurred by the taxpayer during the taxable year in carrying on any trade or business of the taxpayer—The term “qualified research expenses” means the sum of the following amounts which are paid or incurred by the taxpayer during the taxable year in carrying on any trade or business of the taxpayer—

§ 41(h)–(i)

(b)(1)(A)–(h)(6)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(h)(6)(B)(B) (B)
regulations to minimize compliance and record-keeping burdens under this subsection, andregulations to minimize compliance and record-keeping burdens under this subsection, and
(h)(6)(C)(C) (C)
regulations for recapturing the benefit of credits determined under section 3111(f) in cases where there is a subsequent adjustment to the payroll tax credit portion of the credit determined under subsection (a), including requiring amended income tax returns in the cases where there is such an adjustment.regulations for recapturing the benefit of credits determined under section 3111(f) in cases where there is a subsequent adjustment to the payroll tax credit portion of the credit determined under subsection (a), including requiring amended income tax returns in the cases where there is such an adjustment.
(i)(i) [inserted: Qualified drug threat mitigation research expenses.—]
[inserted: For purposes of this section—]
(i)(1)(1) [inserted: Qualified drug threat mitigation research expenses.—]
[inserted: The term “qualified drug threat mitigation research expenses” means the qualified research expenses which would be determined under subsection (b) if “qualified drug threat mitigation research” were substituted for “qualified research” each place it appears therein.]
(i)(2)(2) [inserted: Qualified drug threat mitigation research.—]
[inserted: The term “qualified drug threat mitigation research” means qualified research which is undertaken for the purpose of discovering information related to mitigating or treating the effects of the use of a specified drug or to preventing, diverting, or intervening in such use. Such term shall not include any clinical research unless such research complies with the policies and guidelines of the National Institutes of Health for clinical research.]
(i)(3)(3) [inserted: Specified drug.—]
(i)(3)(A)(A) [inserted: In general.—]
[inserted: The term “specified drug” means any emerging drug, fentanyl, fentanyl-related substance, or methamphetamine.]
(i)(3)(B)(B) [inserted: Emerging drug.—]
[inserted: The term “emerging drug” means a drug designated as an emerging drug threat under section 709(c) of the Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1708(c)). Such term shall include any such drug for any taxable year if such designation is in effect under such section at any time during such taxable year.]
(i)(3)(C)(C) [inserted: Fentanyl-related substance.—]
[inserted: The term “fentanyl-related substance” means any substance that is structurally related to fentanyl by 1 or more of the following modifications:]
(i)(3)(C)(i)(i) [inserted: ]
[inserted: By replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle.]
(i)(3)(C)(ii)(ii) [inserted: ]
[inserted: By substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups.]
(i)(3)(C)(iii)(iii) [inserted: ]
[inserted: By substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups.]
(i)(3)(C)(iv)(iv) [inserted: ]
[inserted: By replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle.]
(i)(3)(C)(v)(v) [inserted: ]
[inserted: By replacement of the N–propionyl group with another acyl group.]

Step through the changes